On April 9, 2021 Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-cancer agent, reported that Sandra Van Schaeybroeck, PhD (Queen’s University Belfast) will be presenting research supporting BOLD-100 as a potential anti-resistance therapy for difficult-to-treat cancers, specifically BRAF-mutant colorectal cancer (Press release, Bold Therapeutics, APR 9, 2021, View Source [SID1234577809]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Van Schaeybroeck’s AACR (Free AACR Whitepaper) poster presentation "Targeting the DNA repair pathway with BOLD-100 in BRAF-mutant colorectal cancer" (Poster# 1183, Session PO.ET04.03 on April 10) highlights the promising research conducted by the Drug Resistance Group at the Patrick G. Johnston Centre for Cancer Research at Queen’s University Belfast, which investigated BOLD-100’s mechanism-of-action and identified promising treatment combinations in difficult-to-treat BRAF-mutant colorectal cancers.
Colon cancer is one of the most frequently diagnosed malignancies in adults, responsible for approximately 11% of all new cases of cancers worldwide and one-third of cancer deaths. BRAF-mutant colorectal cancers comprise 10% of those patients, and this subgroup has morphological, clinical, and therapeutic characteristics that differ substantially from patients without this genetic alteration. Importantly, there is no established standard of care for BRAF-mutant colorectal cancer, which is associated with a particularly poor prognosis and a median OS of less than 12 months versus more than 30 months for BRAF wild type metastatic colorectal cancer (mCRC), with V600E BRAF-mutated colorectal cancer being the most challenging subtype.
"BOLD-100 has a unique and complex mechanism-of-action and has potential in various challenging cancer subtypes, such as V600E BRAF-mutated colorectal cancer," stated Van Schaeybroeck. "This study further elucidated the mechanism-of-action for BOLD-100 and identified potentially synergistic drug-drug combinations for future investigation."
The AACR (Free AACR Whitepaper) Annual Meeting provides an opportunity to discuss the latest discoveries in cancer research and highlights the work being done by institutions around the world. This year’s virtual conference is taking place April 10-15 and May 17-21.
"Bold Therapeutics has developed a global consortium of world-class academic collaborators to investigate the potential of BOLD-100 as a revolutionary first-in-class anti-cancer agent that targets both ER stress and DNA repair pathways," said Mark Bazett, PhD, Director of Preclinical Development at Bold Therapeutics. "We look forward to connecting with interested researchers at AACR (Free AACR Whitepaper) 2021 to further develop this novel therapy."
Bold Therapeutics is headquartered in Vancouver, British Columbia, Canada. BOLD-100 is currently being investigated in a Phase 1b/2 study in combination with FOLFOX in the treatment of advanced gastrointestinal cancers at six sites in Canada, with additional sites opening in the United States and South Korea in late 2021.